These results confirmed that the anti-tumor effect of BTZ was maintained in the BTZ/nHA@SA scaffold, while at the BTZ concentration of 5–10 nM in BTZ/nHA@SA scaffold, a synchronous tumors inhibition and enhanced osteogenesis may be obtained. The gene discussed is CASC3; the disease is neoplasm.